All News

Machine learning algorithm demonstrated high level of accuracy (88%) and precision (0.95) in diagnosing potential cases of axSpA ⭐️Is there a role for ML to facilitate faster rheum eval for suspicious axSpA cases? Abs#1922 #ACR21 @RheumNow https://t.co/tAPfROPICU https://t.co/HJD37B9jZw

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Is there a relationship between the weather and RA disease activity?⛈️ #ACR21 Abs#1912 🌡️Temperature & humidity significantly affect pain, TJC & SJC 🌦️PGA was mostly influenced by humidity Should we take the weather into account when assessing patients? @RheumNow https://t.co/e3PewZWkLR
Mrinalini Dey DrMiniDey ( View Tweet)
RA ILD survival. The ‘smoking’ gun! RA ILD in VA pts mostly menand smokers - data showed disease activity of #RheumatoidArthritis & ⬆️HAQ both reduced survival independently #ACRBest #ACR21 abst#1918 @RheumNow https://t.co/8GD7rHV07t
Janet Pope Janetbirdope ( View Tweet)
Preventive Window of Opportunity in RA? Dr. Aurelie Najm ( @AurelieRheumo) discusses abstract #0455 presented at the #ACR21 annual meeting. https://t.co/bCN1k5hhUc https://t.co/gpEHk0XIRc

Links:

Dr. John Cush RheumNow ( View Tweet)
PsO vs PsA patient and disease characteristics COPPAR registry: PsO pts 🔼mean BSA Both 🔼 % of biologic therapy sPGA and PASI 🔼PsO 🔽QOL and physical health in PsA 🔼daily work impairment PsA Abst # 1779 #ACR21 @RheumNow

swethaann23 swethaann23 ( View Tweet)

🚫Infection risk after COVID vaccination: US database 536 954 Controls and 47 303 pts w/ RMDs 〽️BNT162b2 19 vs. 36/1000 〽️ mRNA-1273 16 vs. 33/1000 〽️Janssen 26 vs. 47/1000 Infections ⬆️ RA, SpA, SLE, SSc, Polymyositis #ACR21 #AbstL16 @RheumNow https://t.co/xzOaFIu06e @RheumNow https://t.co/tmr4USETJ3

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
#ACR21 2022 ACR/EULAR Large Vessel Vasculitis Criteria: 🌎One reason for updating 31 year old criteria -> now an international effort that better reflects heterogeneous global disease @RheumNow https://t.co/6YWmabNzuH https://t.co/YXm85uQZCK

Links:

Eric Dein ericdeinmd ( View Tweet)
#ACR21 #Abstr1909 📢We need to stress the importance of hydroxychloroquine adherence to our patients. Adherence (>90% of the time) reduced premature CVD mortality by 52% in #rheumatoidarthritis and #lupus. The study didn’t adjust for smoking @RheumNow https://t.co/D9pGqwWhje https://t.co/R6r3cSexUB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Looking forward to the #ACR21 roundup by Drs. Cush and Kavanaugh at 7pm EST tonight. Always entertaining and informative. A highlight of ACR for me. We met in person the last time in Atlanta #ACR19. It’s virtual & the link is at @RheumNow Hope to meet in person again #ACR22 🤞 https://t.co/pgAcBExL7G
Dr. Antoni Chan synovialjoints ( View Tweet)
Can we predict who will develop #RA-ILD? Perhaps anti-MAA is the answer! #ACR21 Abs#1916 👉🏼⬆️anti-MAA antibody assoc with incident ILD risk 👉🏼Associations are antigen & isotype dependent 👉🏼Antibody measurement may be useful to risk stratify for RA-ILD @RheumNow https://t.co/nC0OkuWtGU
Mrinalini Dey DrMiniDey ( View Tweet)
ORAL Surveillance: MACE and malignancy are getting all the attention... but did you know that non-zoster infections are also more likely with tofacitinib vs TNFis? #ACR21 ABST1684 @RheumNow https://t.co/GiBkvPYs4j
David Liew drdavidliew ( View Tweet)
ACR/EULAR Classification Criteria for Large Vessel Vasculitis (TAK/GCA), updated from prior to include imaging Must emphasize typical disclaimers; these are for classification, not specifically for diagnosis Great effort and useful result, esp for trials #ACR21 @petercgrayson https://t.co/IYFyh5oYBT
Mike Putman EBRheum ( View Tweet)
⭐️Ustekinumab+MTX vs. UST+PBO in PsA? ➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function. *️⃣Thus, no evident to add or maintain ongoing MTX when starting UST Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR21 2022 ACR/EULAR GCA Criteria ▶️Classification, NOT diagnostic! ⭐️Must be >50yo ⭐️Clinical, lab, imaging, and biopsy findings +TA biopsy or Halo sign = 5 points, 6+ points needed for classification @RheumNow https://t.co/6YWmabNzuH https://t.co/cZVrWA02U6

Links:

Eric Dein ericdeinmd ( View Tweet)
Once again #steroids are bad in #RheumatoidArthritis from 2 large admin databases in age >65 in Medicare data, not in younger pts -Optum data. Clear dose response #ACR21 #ACRBest @RheumNow abst#1915 https://t.co/XL93jty7C9
Janet Pope Janetbirdope ( View Tweet)
#ACR21 Abs#1915 👉🏼Chronic steroid use in older adults on stable DMARD therapy assoc w/ ⬆️CV risk 👉🏼Risk even present among older adults receiving low dose ≤5mg/day 👉🏼Larger studies needed in younger healthier adults @RheumNow https://t.co/Lsj5YBz7IG
Mrinalini Dey DrMiniDey ( View Tweet)
Congratulations @KenSaag the 85th President of @ACRheum Under your guidance we will flourish as a team that “is there for our members so they can be there for their patients”. #ACR21 #RheumatologyIsAmazing

David Karp DrDavidKarp ( View Tweet)

#ACR21 2022 ACR/EULAR TAK Criteria ▶️Classification, NOT diagnostic! ⭐️Must be <60 yo, needs vasculitis on imaging ⭐️Clinical criteria + imaging finding (more points for more arteries, 3 pt for abd aorta with renal or mesenteric involvement) @RheumNow https://t.co/6YWmabNzuH https://t.co/fJka2a9tqm

Links:

Eric Dein ericdeinmd ( View Tweet)
HCQ adherence (>90%) associated with 52% reduced cardiovascular mortality in RA and SLE. Seen for MI, stroke, not VTE. Abstr#1909 #ACR21 @RheumNow https://t.co/5UncmqZVNp
Richard Conway RichardPAConway ( View Tweet)
Long-term low dose glucocorticoid use associated ⬆️cardiovascular risk. Clear effect in Medicare population (older), not evident in Optum (younger). Dose dependent. Abstr#1915 #ACR21 @RheumNow https://t.co/oFet3Hhsfo
Richard Conway RichardPAConway ( View Tweet)
×